The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilars: Still Waiting for Promise to Materialize

Biosimilars: Still Waiting for Promise to Materialize

January 17, 2018 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

SAN DIEGO—The potential impact of biosimilars on rheumatology practices was much in evidence at the 2017 ACR/ARHP Annual Meeting Nov. 3–8, although speakers made it clear that this impact has, so far, failed to affect their prescribing behaviors. A Great Debate on the purported benefits of biosimilars for rheumatology practice was held. A second session addressed the Changing Landscape of Biosimilar Medicine, clarifying definitions and proposing opportunities for the rapidly evolving branch of rheumatology research.

You Might Also Like
  • The Science Behind Biosimilars
  • Biosimilars: How Do They Affect Patient Care & Safety?
  • Biosimilars to Raise Unique Questions
Explore This Issue
February 2018

A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. These treatments receive approval from the U.S. Food & Drug Administration (FDA) through a specific pathway for biosimilar evaluation, Jonathan Kay, MD, professor of medicine and Timothy S. and Elaine L. Peterson Chair in Rheumatology at the University of Massachusetts Medical School in Worcester, explained in the latter session. The promise is that the biosimilar should be as effective and safe as its reference product—but considerably less costly, thereby improving access to treatment for patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Biosimilarity means the product is highly similar to its reference biologic product, although there can be minor differences in the clinically inactive components. The goal in evaluating biosimilars is to demonstrate that no clinically meaningful differences exist between the biosimilar and its reference product in terms of safety, purity or potency, Dr. Kay said. However, biologics are produced in living cells, and the potential for variation at each stage of production exists; thus, a biosimilar is not identical to its reference product.

“Just like its reference product, the biologic agent upon which the biosimilar is based, biosimilars are subject to batch variability and ‘drift.’ Despite differences between batches, a batch of a biologic is released without any requirement for notification of healthcare professionals or patients if these differences are within pre-specified, ‘proven acceptable ranges,’” Dr. Kay said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A biosimilar product undergoes rigorous testing directly in comparison with its reference product so that any differences between the biosimilar and its reference product are shown not to cause clinically significant effects.

The FDA standard for approval for use in human patients is that the biosimilar must show equivalence to the reference product, according to the “totality of evidence.” The goal is to establish similarity by demonstrating equivalence in pharmacokinetics, efficacy and comparability in safety. The development process for a biosimilar is abbreviated when compared with the process for original biologics, with smaller numbers of patients in trials to expedite the approval process. 

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Meeting Reports Tagged With: 2017 ACR/ARHP Annual Meeting, ACR/ARHP Annual Meeting, Biologics & Biosimilars, biosimilar, drug pricing, Drug Updates, interchangeabilityIssue: February 2018

You Might Also Like:
  • The Science Behind Biosimilars
  • Biosimilars: How Do They Affect Patient Care & Safety?
  • Biosimilars to Raise Unique Questions
  • Biosimilars Great Debate: To Switch or Not?

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.